Total Payments
$13,273
2024 Payments
$2,591
Companies
35
Transactions
674
Medicare Patients
4,223
Medicare Billing
$921,490
Payment Breakdown by Category
Food & Beverage$12,933 (97.4%)
Education$339.75 (2.6%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $12,933 | 649 | 97.4% |
| Education | $339.75 | 25 | 2.6% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Gilead Sciences, Inc. | $2,681 | 128 | $0 (2024) |
| Merck Sharp & Dohme LLC | $1,988 | 114 | $0 (2024) |
| ViiV Healthcare Company | $1,115 | 78 | $0 (2024) |
| Shionogi Inc | $1,114 | 33 | $0 (2024) |
| Astellas Pharma US Inc | $944.58 | 52 | $0 (2024) |
| Insmed, Inc. | $667.66 | 34 | $0 (2024) |
| Melinta Therapeutics, LLC | $585.02 | 39 | $0 (2024) |
| Allergan, Inc. | $550.83 | 32 | $0 (2020) |
| La Jolla Pharmaceutical Company | $484.21 | 14 | $0 (2024) |
| ABBVIE INC. | $447.17 | 20 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $2,591 | 104 | Gilead Sciences, Inc. ($499.41) |
| 2023 | $2,107 | 94 | Gilead Sciences, Inc. ($624.86) |
| 2022 | $1,686 | 82 | Gilead Sciences, Inc. ($452.61) |
| 2021 | $750.63 | 44 | Gilead Sciences, Inc. ($225.27) |
| 2020 | $566.59 | 27 | Gilead Sciences, Inc. ($148.11) |
| 2019 | $1,838 | 114 | Merck Sharp & Dohme Corporation ($482.97) |
| 2018 | $1,926 | 107 | Merck Sharp & Dohme Corporation ($437.63) |
| 2017 | $1,808 | 102 | Merck Sharp & Dohme Corporation ($516.55) |
All Payment Transactions
674 individual payment records from CMS Open Payments — Page 1 of 27
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | Shionogi Inc | Fetroja (Drug) | Food and Beverage | In-kind items and services | $24.61 | General |
| Category: Infections and Infectious Diseases | ||||||
| 12/16/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $22.70 | General |
| 12/11/2024 | La Jolla Pharmaceutical Company | XERAVA (Drug) | Food and Beverage | In-kind items and services | $27.02 | General |
| Category: TETRACYCLINE CLASS ANTIBACTERIAL | ||||||
| 12/11/2024 | Melinta Therapeutics, LLC | Rezzayo (Drug), Kimyrsa, Orbactiv | Food and Beverage | In-kind items and services | $19.23 | General |
| Category: ANTIFUNGALS | ||||||
| 12/10/2024 | Astellas Pharma US Inc | Cresemba (Drug) | Food and Beverage | In-kind items and services | $22.92 | General |
| Category: Infectious Diseases | ||||||
| 12/09/2024 | Insmed, Inc. | Arikayce (Drug) | Food and Beverage | In-kind items and services | $21.08 | General |
| Category: Respiratory | ||||||
| 12/02/2024 | ViiV Healthcare Company | DOVATO (Drug) | Food and Beverage | In-kind items and services | $17.79 | General |
| Category: HIV | ||||||
| 11/25/2024 | ViiV Healthcare Company | CABENUVA (Biological) | Food and Beverage | In-kind items and services | $17.94 | General |
| Category: HIV | ||||||
| 11/21/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $16.80 | General |
| 11/18/2024 | Ferring Pharmaceuticals Inc. | REBYOTA (Biological) | Food and Beverage | In-kind items and services | $14.42 | General |
| Category: GASTROENTEROLOGY | ||||||
| 11/13/2024 | Astellas Pharma US Inc | Cresemba (Drug) | Food and Beverage | In-kind items and services | $112.63 | General |
| Category: Infectious Diseases | ||||||
| 11/13/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $26.30 | General |
| 11/07/2024 | Merck Sharp & Dohme LLC | DELSTRIGO (Drug) | Food and Beverage | In-kind items and services | $22.91 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 11/06/2024 | Shionogi Inc | Fetroja (Drug) | Food and Beverage | In-kind items and services | $24.04 | General |
| Category: Infections and Infectious Diseases | ||||||
| 11/05/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $24.49 | General |
| 10/30/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $15.97 | General |
| 10/23/2024 | Astellas Pharma US Inc | Cresemba (Drug) | Food and Beverage | In-kind items and services | $19.63 | General |
| Category: Infectious Diseases | ||||||
| 10/22/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $34.06 | General |
| 10/21/2024 | La Jolla Pharmaceutical Company | XERAVA (Drug) | Food and Beverage | In-kind items and services | $26.89 | General |
| Category: TETRACYCLINE CLASS ANTIBACTERIAL | ||||||
| 10/15/2024 | Ferring Pharmaceuticals Inc. | REBYOTA (Biological) | Food and Beverage | In-kind items and services | $15.14 | General |
| Category: GASTROENTEROLOGY | ||||||
| 10/14/2024 | Insmed, Inc. | Arikayce (Drug) | Food and Beverage | In-kind items and services | $21.55 | General |
| Category: Respiratory | ||||||
| 10/10/2024 | Shionogi Inc | Fetroja (Drug) | Food and Beverage | In-kind items and services | $22.85 | General |
| Category: Infections and Infectious Diseases | ||||||
| 10/02/2024 | Insmed, Inc. | Arikayce (Drug) | Food and Beverage | In-kind items and services | $20.79 | General |
| Category: Respiratory | ||||||
| 09/30/2024 | Invivyd Inc | PEMGARDA (Biological) | Food and Beverage | In-kind items and services | $26.63 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 09/26/2024 | AIMMUNE THERAPEUTICS, INC. | VOWST (Biological) | Food and Beverage | In-kind items and services | $25.25 | General |
| Category: GI | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 12 | 786 | 75,921 | $714,602 | $198,998 |
| 2022 | 13 | 1,000 | 25,354 | $538,645 | $211,189 |
| 2021 | 14 | 1,097 | 50,963 | $647,907 | $230,945 |
| 2020 | 18 | 1,340 | 74,242 | $808,573 | $280,358 |
Total Patients
4,223
Total Services
226,480
Medicare Billing
$921,490
Procedure Codes
57
All Medicare Procedures & Services
57 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 183 | 1,232 | $214,580 | $74,088 | 34.5% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 135 | 561 | $130,655 | $50,969 | 39.0% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 159 | 170 | $66,750 | $21,819 | 32.7% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 98 | 475 | $68,050 | $17,795 | 26.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 64 | 116 | $23,700 | $10,310 | 43.5% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 32 | 200 | $40,000 | $9,023 | 22.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 34 | 51 | $13,145 | $6,785 | 51.6% |
| J0878 | Injection, daptomycin, 1 mg | Office | 2023 | 17 | 71,850 | $111,555 | $2,794 | 2.5% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 25 | 27 | $8,350 | $2,408 | 28.8% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 15 | 15 | $5,225 | $1,767 | 33.8% |
| J1335 | Injection, ertapenem sodium, 500 mg | Office | 2023 | 11 | 80 | $12,000 | $777.11 | 6.5% |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | Office | 2023 | 13 | 1,144 | $20,592 | $462.59 | 2.2% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 223 | 1,704 | $195,960 | $92,544 | 47.2% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 116 | 440 | $68,200 | $33,844 | 49.6% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 161 | 169 | $54,925 | $24,358 | 44.3% |
| 99231 | Follow-up hospital inpatient care per day, typically 15 minutes | Facility | 2022 | 138 | 729 | $65,610 | $21,597 | 32.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 85 | 164 | $24,600 | $14,619 | 59.4% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 79 | 83 | $20,750 | $8,622 | 41.6% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2022 | 59 | 137 | $27,400 | $6,044 | 22.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 30 | 36 | $7,020 | $4,731 | 67.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 22 | 32 | $3,200 | $2,072 | 64.7% |
| J1335 | Injection, ertapenem sodium, 500 mg | Office | 2022 | 23 | 87 | $13,050 | $1,042 | 8.0% |
| J0878 | Injection, daptomycin, 1 mg | Office | 2022 | 21 | 21,300 | $44,730 | $810.15 | 1.8% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2022 | 16 | 33 | $5,280 | $732.75 | 13.9% |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | Office | 2022 | 27 | 440 | $7,920 | $174.09 | 2.2% |
About Dr. John Meek, MD
Dr. John Meek, MD is a Infectious Disease healthcare provider based in Lexington, Kentucky. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/09/2005. The National Provider Identifier (NPI) number assigned to this provider is 1891796298.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. John Meek, MD has received a total of $13,273 in payments from pharmaceutical and medical device companies, with $2,591 received in 2024. These payments were reported across 674 transactions from 35 companies. The most common payment nature is "Food and Beverage" ($12,933).
As a Medicare-enrolled provider, Meek has provided services to 4,223 Medicare beneficiaries, totaling 226,480 services with total Medicare billing of $921,490. Data is available for 4 years (2020–2023), covering 57 distinct procedure/service records.
Ad
Practice Information
- Specialty Infectious Disease
- Location Lexington, KY
- Active Since 08/09/2005
- Last Updated 03/05/2008
- Taxonomy Code 207RI0200X
- Entity Type Individual
- NPI Number 1891796298
Products in Payments
- Fetroja (Drug) $1,114
- ZERBAXA (Drug) $803.90
- Arikayce (Drug) $667.66
- Cresemba (Drug) $538.63
- DOVATO (Drug) $532.78
- DIFICID (Drug) $502.72
- AVYCAZ (Drug) $482.02
- XERAVA (Drug) $464.66
- VIBATIV (Drug) $324.33
- Veklury (Drug) $318.67
- Vabomere (Drug) $312.57
- NUZYRA (Drug) $290.25
- ISENTRESS (Drug) $259.14
- Mavyret (Drug) $245.38
- BEVYXXA (Drug) $241.15
- Biktarvy (Drug) $229.59
- PIFELTRO (Drug) $155.42
- AMBISOME (Drug) $154.09
- VOWST (Biological) $153.11
- Xerava (Drug) $153.04
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Infectious Disease Doctors in Lexington
Dr. David Dougherty, M.d, M.D
Infectious Disease — Payments: $110,300
Infectious Disease $110,300
Daniel Rodrigue, Md, MD
Infectious Disease — Payments: $50,659
Infectious Disease $50,659
Charles Rose
Infectious Disease — Payments: $42,996
Infectious Disease $42,996
Dr. Marty Allen, M.d, M.D
Infectious Disease — Payments: $39,505
Infectious Disease $39,505
Mark Dougherty, Md, MD
Infectious Disease — Payments: $12,643
Infectious Disease $12,643
Dr. Andrea Banks, Md, MD
Infectious Disease — Payments: $9,877
Infectious Disease $9,877